Prelude Capital Management’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$191K Sell
19,248
-2,300
-11% -$20.2K 0.01% 1116
2026
Q2
$175K Buy
21,548
+3,100
+17% +$22.7K 0.01% 1010
2026
Q1
$118K Sell
18,448
-13,700
-43% -$88.3K 0.01% 1023
2025
Q4
$191K Sell
32,148
-6,274
-16% -$33.3K 0.01% 1077
2025
Q3
$204K Buy
38,422
+5,000
+15% +$21.2K 0.02% 937
2025
Q2
$115K Sell
33,422
-4,278
-11% -$13.7K 0.01% 887
2025
Q1
$112K Buy
37,700
+12,900
+52% +$40.4K 0.01% 1026
2024
Q4
$75.6K Buy
+24,800
New +$72.2K ﹤0.01% 1122
2019
Q3
– Sell
-120
Closed -$2K – 1957
2019
Q2
$2K Sell
120
-280
-70% -$6.45K ﹤0.01% 1574
2019
Q1
$16K Hold
400
– – ﹤0.01% 1349
2018
Q4
$8K Buy
+400
New +$12K ﹤0.01% 1424
2018
Q2
– Sell
-8,723
Closed -$594K – 1870
2018
Q1
$594K Sell
8,723
-3,636
-29% -$272K 0.04% 398
2017
Q4
$1.22M Buy
+12,359
New +$1.38M 0.1% 213
2017
Q2
– Sell
-20,335
Closed -$756K – 1785
2017
Q1
$756K Buy
+20,335
New +$742K 0.07% 274
2015
Q3
– Sell
-1,689
Closed -$197K – 1708
2015
Q2
$197K Hold
1,689
– – 0.03% 603
2015
Q1
$399K Buy
+1,689
New +$361K 0.06% 406

Other funds holding PBYI

Prelude Capital Management's PBYI Position: Q3 2026 in Review

Prelude Capital Management reduced its Puma Biotechnology (PBYI) stake by 11% in Q3 2026, selling an estimated $20.2K and leaving 19,248 shares worth $191K. The position accounts for 0.01% of the portfolio, ranked #1116.

Prelude Capital Management first reported a position in PBYI in Q1 2015 and has held it in 16 quarters since. The position peaked at $1.22M in Q4 2017. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2026.

  • Prelude Capital Management held 19,248 shares of Puma Biotechnology worth $191K as of Q3 2026.
  • Prelude Capital Management sold 2,300 Puma Biotechnology shares in Q3 2026, an estimated $20.2K.
  • Puma Biotechnology made up 0.01% of Prelude Capital Management's portfolio in Q3 2026, its #1116 holding.
  • Prelude Capital Management first reported a position in Puma Biotechnology in Q1 2015 and has held it in 16 quarters since.
  • Prelude Capital Management's Puma Biotechnology position peaked at $1.22M in Q4 2017.
  • 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2026.

Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.